English
简体中文
Total: £ 56.28
Published Date: 2025-11-11 | Pages: 118 | Tables: 129 | Medical Care
The global AAV Vector-Based Gene Therapy Drugs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
AAV vector-based gene therapy drugs are a class of therapeutic agents used in the treatment of genetic disorders and certain diseases These drugs utilize AAV vectors, which are small, non-enveloped viruses that have a low pathogenic profile and are capable of delivering genetic material into host cells. The genetic material, which be a functional gene or a therapeutic gene, is inserted into the AAV vector and then introduced into the patient's cells, where it is intended to correct genetic mutations or produce therapeutic proteins. AAV vector-based gene therapy has shown promising results in clinical trials for conditions such as Leber congenital amaurosis, spinal muscular atrophy, and certain retinal diseases.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
AAV Vector-Based Gene Therapy Drugs leading manufacturers including uniQure, Spark Therapeutics, AveXis (Novartis), PTC Therapeutics, BioMarin, Sarepta Therapeutics, Roche, Pfizer, etc., dominate supply; the top five capture approximately % of global revenue, with uniQure leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global AAV Vector-Based Gene Therapy Drugs market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
uniQure
Spark Therapeutics
AveXis (Novartis)
PTC Therapeutics
BioMarin
Sarepta Therapeutics
Roche
Pfizer
Segment by Type
AAV2 Vector
AAV5 Vector
Others
Segment by Application
Hospital
Diagnostic and Testing Laboratories
Academic and Research Organizations
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the AAV Vector-Based Gene Therapy Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to AAV Vector-Based Gene Therapy Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global AAV Vector-Based Gene Therapy Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 AAV2 Vector
1.2.3 AAV5 Vector
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global AAV Vector-Based Gene Therapy Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Diagnostic and Testing Laboratories
1.3.4 Academic and Research Organizations
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global AAV Vector-Based Gene Therapy Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global AAV Vector-Based Gene Therapy Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global AAV Vector-Based Gene Therapy Drugs Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global AAV Vector-Based Gene Therapy Drugs Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 AAV2 Vector Market Size by Players
3.3.2 AAV5 Vector Market Size by Players
3.3.3 Others Market Size by Players
3.4 Global AAV Vector-Based Gene Therapy Drugs Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global AAV Vector-Based Gene Therapy Drugs Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global AAV Vector-Based Gene Therapy Drugs Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America AAV Vector-Based Gene Therapy Drugs Market Size by Type (2020-2031)
6.4 North America AAV Vector-Based Gene Therapy Drugs Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America AAV Vector-Based Gene Therapy Drugs Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe AAV Vector-Based Gene Therapy Drugs Market Size by Type (2020-2031)
7.4 Europe AAV Vector-Based Gene Therapy Drugs Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe AAV Vector-Based Gene Therapy Drugs Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Size by Type (2020-2031)
8.4 Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America AAV Vector-Based Gene Therapy Drugs Market Size by Type (2020-2031)
9.4 Central and South America AAV Vector-Based Gene Therapy Drugs Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America AAV Vector-Based Gene Therapy Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa AAV Vector-Based Gene Therapy Drugs Market Size by Type (2020-2031)
10.4 Middle East and Africa AAV Vector-Based Gene Therapy Drugs Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa AAV Vector-Based Gene Therapy Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 uniQure
11.1.1 uniQure Corporation Information
11.1.2 uniQure Business Overview
11.1.3 uniQure AAV Vector-Based Gene Therapy Drugs Product Features and Attributes
11.1.4 uniQure AAV Vector-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.1.5 uniQure AAV Vector-Based Gene Therapy Drugs Revenue by Product in 2024
11.1.6 uniQure AAV Vector-Based Gene Therapy Drugs Revenue by Application in 2024
11.1.7 uniQure AAV Vector-Based Gene Therapy Drugs Revenue by Geographic Area in 2024
11.1.8 uniQure AAV Vector-Based Gene Therapy Drugs SWOT Analysis
11.1.9 uniQure Recent Developments
11.2 Spark Therapeutics
11.2.1 Spark Therapeutics Corporation Information
11.2.2 Spark Therapeutics Business Overview
11.2.3 Spark Therapeutics AAV Vector-Based Gene Therapy Drugs Product Features and Attributes
11.2.4 Spark Therapeutics AAV Vector-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.2.5 Spark Therapeutics AAV Vector-Based Gene Therapy Drugs Revenue by Product in 2024
11.2.6 Spark Therapeutics AAV Vector-Based Gene Therapy Drugs Revenue by Application in 2024
11.2.7 Spark Therapeutics AAV Vector-Based Gene Therapy Drugs Revenue by Geographic Area in 2024
11.2.8 Spark Therapeutics AAV Vector-Based Gene Therapy Drugs SWOT Analysis
11.2.9 Spark Therapeutics Recent Developments
11.3 AveXis (Novartis)
11.3.1 AveXis (Novartis) Corporation Information
11.3.2 AveXis (Novartis) Business Overview
11.3.3 AveXis (Novartis) AAV Vector-Based Gene Therapy Drugs Product Features and Attributes
11.3.4 AveXis (Novartis) AAV Vector-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.3.5 AveXis (Novartis) AAV Vector-Based Gene Therapy Drugs Revenue by Product in 2024
11.3.6 AveXis (Novartis) AAV Vector-Based Gene Therapy Drugs Revenue by Application in 2024
11.3.7 AveXis (Novartis) AAV Vector-Based Gene Therapy Drugs Revenue by Geographic Area in 2024
11.3.8 AveXis (Novartis) AAV Vector-Based Gene Therapy Drugs SWOT Analysis
11.3.9 AveXis (Novartis) Recent Developments
11.4 PTC Therapeutics
11.4.1 PTC Therapeutics Corporation Information
11.4.2 PTC Therapeutics Business Overview
11.4.3 PTC Therapeutics AAV Vector-Based Gene Therapy Drugs Product Features and Attributes
11.4.4 PTC Therapeutics AAV Vector-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.4.5 PTC Therapeutics AAV Vector-Based Gene Therapy Drugs Revenue by Product in 2024
11.4.6 PTC Therapeutics AAV Vector-Based Gene Therapy Drugs Revenue by Application in 2024
11.4.7 PTC Therapeutics AAV Vector-Based Gene Therapy Drugs Revenue by Geographic Area in 2024
11.4.8 PTC Therapeutics AAV Vector-Based Gene Therapy Drugs SWOT Analysis
11.4.9 PTC Therapeutics Recent Developments
11.5 BioMarin
11.5.1 BioMarin Corporation Information
11.5.2 BioMarin Business Overview
11.5.3 BioMarin AAV Vector-Based Gene Therapy Drugs Product Features and Attributes
11.5.4 BioMarin AAV Vector-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.5.5 BioMarin AAV Vector-Based Gene Therapy Drugs Revenue by Product in 2024
11.5.6 BioMarin AAV Vector-Based Gene Therapy Drugs Revenue by Application in 2024
11.5.7 BioMarin AAV Vector-Based Gene Therapy Drugs Revenue by Geographic Area in 2024
11.5.8 BioMarin AAV Vector-Based Gene Therapy Drugs SWOT Analysis
11.5.9 BioMarin Recent Developments
11.6 Sarepta Therapeutics
11.6.1 Sarepta Therapeutics Corporation Information
11.6.2 Sarepta Therapeutics Business Overview
11.6.3 Sarepta Therapeutics AAV Vector-Based Gene Therapy Drugs Product Features and Attributes
11.6.4 Sarepta Therapeutics AAV Vector-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.6.5 Sarepta Therapeutics Recent Developments
11.7 Roche
11.7.1 Roche Corporation Information
11.7.2 Roche Business Overview
11.7.3 Roche AAV Vector-Based Gene Therapy Drugs Product Features and Attributes
11.7.4 Roche AAV Vector-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.7.5 Roche Recent Developments
11.8 Pfizer
11.8.1 Pfizer Corporation Information
11.8.2 Pfizer Business Overview
11.8.3 Pfizer AAV Vector-Based Gene Therapy Drugs Product Features and Attributes
11.8.4 Pfizer AAV Vector-Based Gene Therapy Drugs Revenue and Gross Margin (2020-2025)
11.8.5 Pfizer Recent Developments
12 AAV Vector-Based Gene Therapy DrugsIndustry Chain Analysis
12.1 AAV Vector-Based Gene Therapy Drugs Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 AAV Vector-Based Gene Therapy Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global AAV Vector-Based Gene Therapy Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global AAV Vector-Based Gene Therapy Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global AAV Vector-Based Gene Therapy Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global AAV Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global AAV Vector-Based Gene Therapy Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global AAV Vector-Based Gene Therapy Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global AAV Vector-Based Gene Therapy Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global AAV Vector-Based Gene Therapy Drugs Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global AAV Vector-Based Gene Therapy Drugs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in AAV Vector-Based Gene Therapy Drugs as of 2024)
Table 11. Global AAV Vector-Based Gene Therapy Drugs Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global AAV Vector-Based Gene Therapy Drugs Companies Headquarters
Table 13. Global AAV Vector-Based Gene Therapy Drugs Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global AAV Vector-Based Gene Therapy Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global AAV Vector-Based Gene Therapy Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global AAV Vector-Based Gene Therapy Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global AAV Vector-Based Gene Therapy Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 21. AAV Vector-Based Gene Therapy Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America AAV Vector-Based Gene Therapy Drugs Growth Accelerators and Market Barriers
Table 25. North America AAV Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe AAV Vector-Based Gene Therapy Drugs Growth Accelerators and Market Barriers
Table 27. Europe AAV Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Growth Accelerators and Market Barriers
Table 29. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America AAV Vector-Based Gene Therapy Drugs Investment Opportunities and Key Challenges
Table 31. Central and South America AAV Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa AAV Vector-Based Gene Therapy Drugs Investment Opportunities and Key Challenges
Table 33. Middle East and Africa AAV Vector-Based Gene Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. uniQure Corporation Information
Table 35. uniQure Description and Major Businesses
Table 36. uniQure Product Features and Attributes
Table 37. uniQure Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. uniQure Revenue Proportion by Product in 2024
Table 39. uniQure Revenue Proportion by Application in 2024
Table 40. uniQure Revenue Proportion by Geographic Area in 2024
Table 41. uniQure AAV Vector-Based Gene Therapy Drugs SWOT Analysis
Table 42. uniQure Recent Developments
Table 43. Spark Therapeutics Corporation Information
Table 44. Spark Therapeutics Description and Major Businesses
Table 45. Spark Therapeutics Product Features and Attributes
Table 46. Spark Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Spark Therapeutics Revenue Proportion by Product in 2024
Table 48. Spark Therapeutics Revenue Proportion by Application in 2024
Table 49. Spark Therapeutics Revenue Proportion by Geographic Area in 2024
Table 50. Spark Therapeutics AAV Vector-Based Gene Therapy Drugs SWOT Analysis
Table 51. Spark Therapeutics Recent Developments
Table 52. AveXis (Novartis) Corporation Information
Table 53. AveXis (Novartis) Description and Major Businesses
Table 54. AveXis (Novartis) Product Features and Attributes
Table 55. AveXis (Novartis) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. AveXis (Novartis) Revenue Proportion by Product in 2024
Table 57. AveXis (Novartis) Revenue Proportion by Application in 2024
Table 58. AveXis (Novartis) Revenue Proportion by Geographic Area in 2024
Table 59. AveXis (Novartis) AAV Vector-Based Gene Therapy Drugs SWOT Analysis
Table 60. AveXis (Novartis) Recent Developments
Table 61. PTC Therapeutics Corporation Information
Table 62. PTC Therapeutics Description and Major Businesses
Table 63. PTC Therapeutics Product Features and Attributes
Table 64. PTC Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. PTC Therapeutics Revenue Proportion by Product in 2024
Table 66. PTC Therapeutics Revenue Proportion by Application in 2024
Table 67. PTC Therapeutics Revenue Proportion by Geographic Area in 2024
Table 68. PTC Therapeutics AAV Vector-Based Gene Therapy Drugs SWOT Analysis
Table 69. PTC Therapeutics Recent Developments
Table 70. BioMarin Corporation Information
Table 71. BioMarin Description and Major Businesses
Table 72. BioMarin Product Features and Attributes
Table 73. BioMarin Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. BioMarin Revenue Proportion by Product in 2024
Table 75. BioMarin Revenue Proportion by Application in 2024
Table 76. BioMarin Revenue Proportion by Geographic Area in 2024
Table 77. BioMarin AAV Vector-Based Gene Therapy Drugs SWOT Analysis
Table 78. BioMarin Recent Developments
Table 79. Sarepta Therapeutics Corporation Information
Table 80. Sarepta Therapeutics Description and Major Businesses
Table 81. Sarepta Therapeutics Product Features and Attributes
Table 82. Sarepta Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Sarepta Therapeutics Recent Developments
Table 84. Roche Corporation Information
Table 85. Roche Description and Major Businesses
Table 86. Roche Product Features and Attributes
Table 87. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Roche Recent Developments
Table 89. Pfizer Corporation Information
Table 90. Pfizer Description and Major Businesses
Table 91. Pfizer Product Features and Attributes
Table 92. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Pfizer Recent Developments
Table 94. Raw Materials Key Suppliers
Table 95. Distributors List
Table 96. Market Trends and Market Evolution
Table 97. Market Drivers and Opportunities
Table 98. Market Challenges, Risks, and Restraints
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. AAV Vector-Based Gene Therapy Drugs Product Picture
Figure 2. Global AAV Vector-Based Gene Therapy Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. AAV2 Vector Product Picture
Figure 4. AAV5 Vector Product Picture
Figure 5. Others Product Picture
Figure 6. Global AAV Vector-Based Gene Therapy Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital
Figure 8. Diagnostic and Testing Laboratories
Figure 9. Academic and Research Organizations
Figure 10. Others
Figure 11. AAV Vector-Based Gene Therapy Drugs Report Years Considered
Figure 12. Global AAV Vector-Based Gene Therapy Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 14. Global AAV Vector-Based Gene Therapy Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global AAV Vector-Based Gene Therapy Drugs Revenue Market Share by Region (2020-2031)
Figure 16. Global AAV Vector-Based Gene Therapy Drugs Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. AAV2 Vector Revenue Market Share by Player in 2024
Figure 19. AAV5 Vector Revenue Market Share by Player in 2024
Figure 20. Others Revenue Market Share by Player in 2024
Figure 21. Global AAV Vector-Based Gene Therapy Drugs Revenue Market Share by Type (2020-2031)
Figure 22. Global AAV Vector-Based Gene Therapy Drugs Revenue Market Share by Application (2020-2031)
Figure 23. North America AAV Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 24. North America Top 5 Players AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 25. North America AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020 - 2031)
Figure 26. North America AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 27. US AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 28. Canada AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 29. Mexico AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 30. Europe AAV Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 31. Europe Top 5 Players AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 32. Europe AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 33. Europe AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 34. Germany AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 35. France AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 36. U.K. AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 37. Italy AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 38. Russia AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Top 8 Players AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 41. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 42. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 43. Indonesia AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 44. Japan AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 45. South Korea AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 46. Australia AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. India AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. Indonesia AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Vietnam AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. Malaysia AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 51. Philippines AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 52. Singapore AAV Vector-Based Gene Therapy Drugs Revenue (2020-2031) & (US$ Million)
Figure 53. Central and South America AAV Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Central and South America Top 5 Players AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 55. Central and South America AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 56. Central and South America AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 57. Brazil AAV Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 58. Argentina AAV Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 59. Middle East and Africa AAV Vector-Based Gene Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 60. Middle East and Africa Top 5 Players AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) in 2024
Figure 61. South America AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
Figure 62. Middle East and Africa AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
Figure 63. GCC Countries AAV Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 64. Israel AAV Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 65. Egypt AAV Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 66. South Africa AAV Vector-Based Gene Therapy Drugs Revenue (2020-2025) & (US$ Million)
Figure 67. AAV Vector-Based Gene Therapy Drugs Industry Chain Mapping
Figure 68. Channels of Distribution (Direct Vs Distribution)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
